SCHEMBL17066933

SCHEMBL17066933

CCn1ccc2cnc(Cl)nc21

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.33
JAK3 P52333 3/20 0.33
JAK1 P23458 2/20 0.33
KMT2A Q03164 2/20 0.33
TYK2 P29597 2/20 0.32
RPS6KA3 P51812 2/20 0.32
CDK4 P11802 3/20 0.32
CCND1 P24385 3/20 0.32
CCND2 P30279 3/20 0.32
CCND3 P30281 3/20 0.32
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MAP3K5 Q99683 1/20 0.31
STAT6 P42226 1/20 0.31
RPS6KA5 O75582 1/20 0.31
CDK1 P06493 2/20 0.30
CDK2 P24941 2/20 0.30
PTK2 Q05397 1/20 0.30
AURKA O14965 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30881456 1.00 JAK2 (0.33) JAK2JAK3JAK1KMT2ATYK2
SCHEMBL22638029 0.82 JAK2 (0.48) JAK2JAK3JAK1TYK2RPS6KA3
SCHEMBL4187055 0.82 GLO1 (0.41) KMT2ACDK4CCND1KDM4EALDH1A1
SCHEMBL20660579 0.81 CYP17A1 (0.36) JAK2JAK1KMT2ARPS6KA3STAT6
SCHEMBL27253521 0.80 JAK1 (0.36) JAK2JAK3JAK1TYK2RPS6KA3
SCHEMBL27845067 0.79 RPS6KA3 (0.36) KMT2ARPS6KA3SMN1; SMN2STAT6PTK2
SCHEMBL28793690 0.79 RPS6KA3 (0.33) KMT2ARPS6KA3STAT6PTK2
SCHEMBL23168749 0.79 JAK2 (0.39) JAK2JAK3JAK1TYK2RPS6KA3
SCHEMBL22686552 0.79 JAK2 (0.39) JAK2JAK3JAK1TYK2RPS6KA3
SCHEMBL29467008 0.79 JAK2 (0.39) JAK2JAK3JAK1TYK2RPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598923-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS The Regents of the University of California (US) 2025-08-13 EP disclosed
US-20240201205-A1 METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
US-20240197682-A1 METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
WO-2024059845-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-21 WO disclosed
WO-2024059845-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-21 WO disclosed
EP-2729448-B1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES INC (US) 2015-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS MAPT, HTT, PSEN1 JAK2 3285/4885JAK3 2296/4885JAK1 3533/4885
US-20240197682-A1 METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS PRNP, PSEN1, SNCA JAK2 4264/4885JAK3 3825/4885JAK1 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.